NYSE:KDMN - Kadmon Stock Price, News, Headlines & Rumors Sign in or create an account to add this stock to your watchlist. Get Started $3.32 -0.04 (-1.19 %) (As of 08/15/2018 04:00 PM ET)Previous Close$3.36Today's Range$3.25 - $3.4052-Week Range$2.07 - $5.86Volume1.09 million shsAverage Volume818,125 shsMarket Capitalization$267.90 millionP/E Ratio-2.34Dividend YieldN/ABeta3.1 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; ROCK inhibitor platform, a rho-associated coiled-coil kinase inhibitor, which is in preclinical development to treat specific fibrotic and neurodegenerative diseases; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Chiromics, LLC; MeiraGTx Limited; AbbVie Inc.; Zydus Pharmaceuticals USA, Inc.; Jinghua Pharmaceutical Group Co., Ltd.; and Camber Pharmaceuticals, Inc. The company is headquartered in New York, New York. Receive KDMN News and Ratings via Email Sign-up to receive the latest news and ratings for KDMN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNYSE:KDMN CUSIPN/A Webwww.kadmon.com Phone212-308-6000 Debt Debt-to-Equity RatioN/A Current Ratio3.10 Quick Ratio3.08 Price-To-Earnings Trailing P/E Ratio-2.34 Forward P/E Ratio-3.46 P/E GrowthN/A Sales & Book Value Annual Sales$12.26 million Price / Sales21.34 Cash FlowN/A Price / CashN/A Book Value($0.49) per share Price / Book-6.78 Profitability EPS (Most Recent Fiscal Year)($1.42) Net Income$-79,770,000.00 Net Margins-856.59% Return on EquityN/A Return on Assets-74.68% Miscellaneous Employees101 Outstanding Shares78,790,000Market Cap$267.90 million Kadmon (NYSE:KDMN) Frequently Asked Questions What is Kadmon's stock symbol? Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN." How were Kadmon's earnings last quarter? Kadmon Holdings Inc (NYSE:KDMN) posted its quarterly earnings data on Thursday, August, 9th. The company reported $0.24 EPS for the quarter, beating the Zacks' consensus estimate of ($0.26) by $0.50. The firm earned $0.36 million during the quarter, compared to the consensus estimate of $0.90 million. View Kadmon's Earnings History. When is Kadmon's next earnings date? Kadmon is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Kadmon. What price target have analysts set for KDMN? 4 brokerages have issued 1 year target prices for Kadmon's stock. Their forecasts range from $3.00 to $25.00. On average, they expect Kadmon's share price to reach $13.25 in the next year. This suggests a possible upside of 299.1% from the stock's current price. View Analyst Price Targets for Kadmon. What is the consensus analysts' recommendation for Kadmon? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kadmon. Are investors shorting Kadmon? Kadmon saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 6,034,787 shares, an increase of 139.3% from the June 15th total of 2,521,749 shares. Based on an average daily trading volume, of 2,191,063 shares, the days-to-cover ratio is currently 2.8 days. Currently, 6.2% of the shares of the stock are short sold. View Kadmon's Current Options Chain. Who are some of Kadmon's key competitors? Some companies that are related to Kadmon include Retrophin (RTRX), Apellis Pharmaceuticals (APLS), Radius Health (RDUS), Assembly Biosciences (ASMB), TG Therapeutics Inc common stock (TGTX), Revance Therapeutics (RVNC), Tricida (TCDA), MacroGenics (MGNX), AMAG Pharmaceuticals (AMAG), Flexion Therapeutics (FLXN), Rocket Pharmaceuticals (RCKT), Omeros (OMER), Amarin (AMRN), Dynavax Technologies (DVAX) and Amphastar Pharmaceuticals (AMPH). Who are Kadmon's key executives? Kadmon's management team includes the folowing people: Dr. Harlan W. Waksal, Pres, CEO & Director (Age 65)Mr. Konstantin Poukalov, Exec. VP, CFO & Principal Accounting Officer (Age 34)Mr. Steven N. Gordon, Chief Admin., Compliance & Legal Officer, Exec. VP & Gen. Counsel (Age 50)Dr. John L. Ryan, Chief Medical Officer & Exec. VP (Age 75)Wei Chen Ph.D., Associate Director of Immunology When did Kadmon IPO? (KDMN) raised $101 million in an IPO on Wednesday, July 27th 2016. The company issued 5,600,000 shares at $16.00-$20.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers. Has Kadmon been receiving favorable news coverage? Media stories about KDMN stock have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kadmon earned a daily sentiment score of 0.14 on Accern's scale. They also gave media headlines about the company an impact score of 46.45 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Kadmon. Who are Kadmon's major shareholders? Kadmon's stock is owned by many different of institutional and retail investors. Top institutional investors include Vivo Capital LLC (13.27%), Acuta Capital Partners LLC (11.50%), BlackRock Inc. (6.05%), Marshall Wace LLP (2.16%), VHCP Management II LLC (1.79%) and AE Wealth Management LLC (0.67%). Company insiders that own Kadmon stock include Daniel S Loeb, Eugene Bauer, Goldentree Asset Management Lp, Harlan Waksal, Konstantin Poukalov and Steven N Gordon. View Institutional Ownership Trends for Kadmon. Which institutional investors are selling Kadmon stock? KDMN stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Spark Investment Management LLC. View Insider Buying and Selling for Kadmon. Which institutional investors are buying Kadmon stock? KDMN stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, BlackRock Inc., Acuta Capital Partners LLC, VHCP Management II LLC, Marshall Wace LLP, Renaissance Technologies LLC, Asymmetry Capital Management L.P. and Schwab Charles Investment Management Inc.. Company insiders that have bought Kadmon stock in the last two years include Daniel S Loeb, Eugene Bauer, Harlan Waksal, Konstantin Poukalov and Steven N Gordon. View Insider Buying and Selling for Kadmon. How do I buy shares of Kadmon? Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Kadmon's stock price today? One share of KDMN stock can currently be purchased for approximately $3.32. How big of a company is Kadmon? Kadmon has a market capitalization of $267.90 million and generates $12.26 million in revenue each year. The company earns $-79,770,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. Kadmon employs 101 workers across the globe. How can I contact Kadmon? Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 212-308-6000 or via email at [email protected] MarketBeat Community Rating for Kadmon (NYSE KDMN)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 140 (Vote Outperform)Underperform Votes: 109 (Vote Underperform)Total Votes: 249MarketBeat's community ratings are surveys of what our community members think about Kadmon and other stocks. Vote "Outperform" if you believe KDMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KDMN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/15/2018 by MarketBeat.com StaffFeatured Article: Are Wall Street analysts' stock ratings worth following?